Redirecting to https://www.businesswire.com/news/home/20260604968959/en/Phase-III-FINDCKD-Results-Show-Bayers-KERENDIA-finerenone-Improved-eGFR-Slope-and-Reduced-Risk-of-a-Composite-Kidney-Cardiovascular-Outcome-in-Adults-with-NonDiabetic-Chronic-Kidney-Disease